nach oben

Erschienen in:

01.08.2013 | Original article

Reirradiation for recurrent malignant brain tumor with radiotherapy or proton beam therapy

Technical considerations based on experience at a single institution

verfasst von: M. Mizumoto, MD, T. Okumura, MD, E. Ishikawa, MD, T. Yamamoto, MD, S. Takano, MD, A. Matsumura, MD, Y. Oshiro, MD, H. Ishikawa, MD, H. Sakurai, MD, K. Tsuboi, MD, PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Radiotherapy for recurrent malignant brain tumors is usually limited because of the dose tolerance of the normal brain tissue. The goal of the study was to evaluate the efficacy and feasibility of reirradiation for patients with recurrent malignant brain tumors.

Patients and methods

The subjects comprised 26 patients with recurrent malignant brain tumors treated with conventional radiotherapy (RT, n = 8), stereotactic radiotherapy (SRT, n = 10), and proton beam therapy (PBT, n = 8) at our institute. Fifteen patients had glioblastoma, 6 had WHO grade 3 glioma, and 5 had other tumors. The dose of initial radiotherapy was 34.5–94.4 Gy. Different radiation schedules were compared using the equivalent dose in 2-Gy fractions.

Results

Reirradiation was completed in all patients without a severe acute reaction. The reirradiation doses were 30–60 Gy (median, 42.3 Gy) and the total doses for the initial and second treatments were 64.5–150.4 Gy (median, 100.0 Gy). Currently, 11 patients are alive (median follow-up period, 19.4 months) and 15 are dead. The median survival and local control periods after reirradiation of the 26 patients were 18.3 and 9.3 months, respectively. For the 15 patients with glioblastoma, these periods were 13.1 and 11.0 months, respectively. Two patients showed radiation necrosis that was treated by surgery or conservative therapy.

Conclusion

Reirradiation for recurrent malignant brain tumor using conventional RT, SRT, or PBT was feasible and effective in selected cases. Further investigation is needed for treatment optimization for a given patient and tumor condition.

(o A) (2010) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2006

Combs SE, Thilmann C, Edler L et al (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23:8863–8869PubMedCrossRef

Combs SE, Widmer V, Thilmann C et al (2005) Stereotactic radiosurgery (SRS), treatment option for recurrent glioblastoma multiforme (GBM). Cancer 104:2168–2173PubMedCrossRef

Fogh SE, Andrews DW, Glass J et al (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048–3053PubMedCrossRef

Fokas E, Wacker U, Gross WG et al (2009) Hypofractionated stereotactic reirradiation of recurrent glioblastomas. Strahlenther Onkol 185:235–240PubMedCrossRef

Kong DS, Lee JI, Park K et al (2008) Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer 112:2046–2051PubMedCrossRef

Minniti G, Armosini V, Salvati M et al (2011) Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol 103:683–691PubMedCrossRef

Mayer R, Sminia P (2008) Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys 70:1350–1360PubMedCrossRef

Fukumitsu N, Okumura T, Mizumoto M et al (2012) Outcome of T4 (International Union Against Cancer Staging System, 7th edition) or recurrent nasal cavity and paranasal sinus carcinoma treated with proton beam. Int J Radiat Oncol Biol Phys 83:704–711PubMed

10.

Igaki H, Tokuuye K, Okumura T et al (2004) Clinical results of proton beam therapy for skull base chordoma. Int J Radiat Oncol Biol Phys 60:1120–1126PubMedCrossRef

11.

Mizumoto M, Tsuboi K, Igaki H et al (2010) Phase I/II trial of hyperfractionated concomitant boost proton radiotherapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys 77:98–105PubMedCrossRef

12.

Mizumoto M, Okumura T, Hashimoto T et al (2011) Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys 81:1039–1045PubMedCrossRef

13.

Oshiro Y, Mizumoto M, Okumura T et al (2012) Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III. J Thorac Oncol 7:370–375PubMedCrossRef

14.

Gerweck LE, Kozin SV (1999) Relative biological effectiveness of proton beams in clinical therapy. Radiother Oncol 50:135–142PubMedCrossRef

15.

Paganetti H, Niemierko A, Ancukiewicz M et al (2002) Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys 53:407–421PubMedCrossRef

16.

Barendsen GW (1982) Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 8:1981–1997PubMedCrossRef

17.

Joiner MC, Van der Kogel AJ (1997) The linear-quadratic approach to fractionation and calculation of isoeffect relationships. In: Steel GG (Ed) Basic clinical radiobiology. Oxford University Press, New York, NY, S 106–112

18.

Mizumoto M, Sugahara S, Nakayama H et al (2010) Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. Strahlenther Onkol 186:482–488PubMedCrossRef

19.

National Cancer Institute (2013) National Cancer Institute common toxicity criteria. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed March 2013

20.

Lorentini S, Amichetti M, Spiazzi L et al (2012) Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. Strahlenther Onkol 188:216–225PubMedCrossRef

21.

Holy R, Piroth M, Pinkawa M et al (2011) Stereotactic Body Radiation Therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 187:245–251PubMedCrossRef

Titel: Reirradiation for recurrent malignant brain tumor with radiotherapy or proton beam therapy
Technical considerations based on experience at a single institution
verfasst von: M. Mizumoto, MD
T. Okumura, MD
E. Ishikawa, MD
T. Yamamoto, MD
S. Takano, MD
A. Matsumura, MD
Y. Oshiro, MD
H. Ishikawa, MD
H. Sakurai, MD
K. Tsuboi, MD, PhD
Publikationsdatum: 01.08.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 8/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0390-6

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Reirradiation for recurrent malignant brain tumor with radiotherapy or proton beam therapy

Technical considerations based on experience at a single institution

Abstract

Background and purpose

Patients and methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background and purpose

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2013

Prognostic impact of VEGF and FLT-1 receptor expression in patients with locally advanced squamous cell carcinoma of the head and neck

Counseling cancer patients on complementary and alternative medicine

Reply to the letter of Junginger et al. Strahlenther Onkol 2013 DOI 10.1007/s00066-013-0353-y

Comment on the editorial of Sautter-Bihl et al. in Strahlentherapie und Onkologie 2013 189:105–110

Radiotherapy in pediatric pilocytic astrocytomas

Risiko von venösen Thromboembolien bei Tumorpatienten, die mit Cisplatin behandelt werden

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie